Spatial Domain (Tier 1)
1,751-1,800 of 2,070
Download spatial tables
Spatial Domain (Tier 1)
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__88_A2,11 | Lung | Primary cancer | 3,636 | Tumor/Malignant | 51.3% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__88_A2,12 | Lung | Primary cancer | 1,485 | Tumor/Malignant | 31.8% | 0.90 | 0.34 |
| NSCLC_38242124__IMC__88_A2,13 | Lung | Primary cancer | 1,977 | Stromal | 44.6% | 0.87 | 0.34 |
| NSCLC_38242124__IMC__88_A2,14 | Lung | Primary cancer | 2,944 | Tumor/Malignant | 37.5% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_A2,15 | Lung | Primary cancer | 2,890 | Other | 30.6% | 0.34 | 1.02 |
| NSCLC_38242124__IMC__88_A2,16 | Lung | Primary cancer | 3,143 | Tumor/Malignant | 86.7% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__88_A2,2 | Lung | Primary cancer | 2,338 | Tumor/Malignant | 40.4% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_A2,3 | Lung | Primary cancer | 1,983 | Tumor/Malignant | 47.3% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__88_A2,4 | Lung | Primary cancer | 3,229 | Tumor/Malignant | 29.2% | 0.87 | 0.33 |
| NSCLC_38242124__IMC__88_A2,5 | Lung | Primary cancer | 1,642 | Stromal | 50.3% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__88_A2,6 | Lung | Primary cancer | 3,461 | Tumor/Malignant | 41.1% | 0.96 | 0.19 |
| NSCLC_38242124__IMC__88_A2,7 | Lung | Primary cancer | 1,860 | Tumor/Malignant | 86.8% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__88_A2,8 | Lung | Primary cancer | 1,169 | Stromal | 49.4% | 0.94 | 0.15 |
| NSCLC_38242124__IMC__88_A2,9 | Lung | Primary cancer | 3,898 | Tumor/Malignant | 42.3% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__88_A3,1 | Lung | Primary cancer | 2,563 | Tumor/Malignant | 45.6% | 0.87 | 0.36 |
| NSCLC_38242124__IMC__88_A3,10 | Lung | Primary cancer | 3,551 | Stromal | 34.1% | 0.76 | 0.59 |
| NSCLC_38242124__IMC__88_A3,11 | Lung | Primary cancer | 1,855 | Stromal | 31.3% | 0.89 | 0.34 |
| NSCLC_38242124__IMC__88_A3,12 | Lung | Primary cancer | 2,749 | Tumor/Malignant | 30.2% | 0.92 | 0.26 |
| NSCLC_38242124__IMC__88_A3,13 | Lung | Primary cancer | 2,710 | Tumor/Malignant | 61.1% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__88_A3,14 | Lung | Primary cancer | 2,364 | Tumor/Malignant | 46.1% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__88_A3,16 | Lung | Primary cancer | 3,270 | Tumor/Malignant | 58.2% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_A3,2 | Lung | Primary cancer | 2,814 | Tumor/Malignant | 73.3% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__88_A3,3 | Lung | Primary cancer | 3,654 | Tumor/Malignant | 38.1% | 0.53 | 0.75 |
| NSCLC_38242124__IMC__88_A3,4 | Lung | Primary cancer | 3,733 | Tumor/Malignant | 82.3% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__88_A3,6 | Lung | Primary cancer | 1,653 | Tumor/Malignant | 38.5% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__88_A3,7 | Lung | Primary cancer | 3,220 | Immune | 32.8% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__88_A3,8 | Lung | Primary cancer | 2,029 | Tumor/Malignant | 58.7% | 0.97 | 0.07 |
| NSCLC_38242124__IMC__88_A3,9 | Lung | Primary cancer | 2,418 | Tumor/Malignant | 26.0% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__88_A4,1 | Lung | Primary cancer | 2,500 | Tumor/Malignant | 37.3% | 0.58 | 0.84 |
| NSCLC_38242124__IMC__88_A4,10 | Lung | Primary cancer | 3,599 | Tumor/Malignant | 56.4% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__88_A4,11 | Lung | Primary cancer | 2,207 | Stromal | 27.2% | 0.90 | 0.29 |
| NSCLC_38242124__IMC__88_A4,12 | Lung | Primary cancer | 3,092 | Tumor/Malignant | 61.2% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__88_A4,13 | Lung | Primary cancer | 2,399 | Tumor/Malignant | 69.7% | 0.93 | 0.16 |
| NSCLC_38242124__IMC__88_A4,14 | Lung | Primary cancer | 1,431 | Stromal | 48.6% | 0.92 | 0.25 |
| NSCLC_38242124__IMC__88_A4,15 | Lung | Primary cancer | 3,532 | Tumor/Malignant | 46.5% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__88_A4,16 | Lung | Primary cancer | 2,852 | Tumor/Malignant | 88.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__88_A4,2 | Lung | Primary cancer | 6,729 | Tumor/Malignant | 38.8% | 0.92 | 0.22 |
| NSCLC_38242124__IMC__88_A4,3 | Lung | Primary cancer | 3,108 | Stromal | 28.3% | 0.35 | 1.01 |
| NSCLC_38242124__IMC__88_A4,4 | Lung | Primary cancer | 3,072 | Tumor/Malignant | 94.0% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_A4,7 | Lung | Primary cancer | 2,900 | Immune | 53.3% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__88_A4,8 | Lung | Primary cancer | 2,901 | Tumor/Malignant | 52.0% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_A4,9 | Lung | Primary cancer | 3,469 | Tumor/Malignant | 30.7% | 0.92 | 0.28 |
| NSCLC_38242124__IMC__88_A5,1 | Lung | Primary cancer | 2,324 | Tumor/Malignant | 85.2% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_A5,10 | Lung | Primary cancer | 2,995 | Tumor/Malignant | 59.6% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__88_A5,11 | Lung | Primary cancer | 4,081 | Tumor/Malignant | 78.1% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_A5,12 | Lung | Primary cancer | 2,371 | Tumor/Malignant | 49.8% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__88_A5,13 | Lung | Primary cancer | 2,420 | Stromal | 34.0% | 0.89 | 0.30 |
| NSCLC_38242124__IMC__88_A5,14 | Lung | Primary cancer | 3,717 | Immune | 39.0% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__88_A5,15 | Lung | Primary cancer | 3,147 | Tumor/Malignant | 40.8% | 0.75 | 0.58 |
| NSCLC_38242124__IMC__88_A5,16 | Lung | Primary cancer | 4,423 | Tumor/Malignant | 59.0% | 0.99 | 0.03 |